CBPO - China Biologic Products Holdings, Inc.
| Previous Close | 90.40 |
| Open | 90.21 |
| Bid | 91.70 x 800 |
| Ask | 103.00 x 900 |
| Day's Range | 89.50 - 92.83 |
| 52 Week Range | 71.85 - 107.44 |
| Volume | 162,826 |
| Avg. Volume | 419,744 |
| Market Cap | 3.058B |
| Beta | 1.29 |
| PE Ratio (TTM) | 39.77 |
| EPS (TTM) | 2.31 |
| Earnings Date | Oct 31, 2018 - Nov 5, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 104.24 |
Markit•6 days agoSee what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.
Short interest is low for CBPO with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETFs that hold CBPO had net inflows of $132 million over the last one-month.
- PR Newswire•7 days ago
China Biologic Names Bing Li as New CEO
BEIJING, Aug. 13, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company's Board of Directors (the "Board") has appointed Dr. Bing Li as the Chief Executive Officer of the Company, effective August 13, 2018. Mr. Zhijun Tong, the former acting CEO, will continue to serve as an executive director of the Board and President of the Company.
- Associated Press•17 days ago
China Biologic Products: 2Q Earnings Snapshot
On a per-share basis, the Beijing-based company said it had profit of 83 cents. Earnings, adjusted for non-recurring costs, were $1.17 per share. The biopharmaceutical company posted revenue of $120.4 ...
- PR Newswire•17 days ago
China Biologic Reports Financial Results for the Second Quarter of 2018
-- 2Q18 Total Sales Up 25.5% YoY and Non-GAAP Adjusted Net Income Down 2.8% YoY in RMB terms, or Total Sales Up 34.8% YoY to $120.4 Million and Net Income Down 7.7% YoY to $28.6 Million in USD terms ...
- PR Newswire•24 days ago
China Biologic Products to Report Second Quarter 2018 Financial Results
BEIJING , July 27, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical ...
- Bloomberg•last month
Ping An Said to Mull Rival Takeover Offer for China Biologic
Ping An Insurance (Group) Co., China’s largest insurer by market value, is considering a rival offer for plasma treatment provider China Biologic Products Holdings Inc., people familiar with the matter said. An arm of Ping An is in talks with other investors about a potential joint bid for Beijing-based China Biologic, according to the people, who asked not to be identified because the information is private. Any offer would be higher than the $110-per-share proposal from Chinese buyout firm Citic Capital, which valued U.S.-listed China Biologic at about $3.6 billion, the people said.
- PR Newswire•2 months ago
China Biologic Announces Results of Its 2018 Annual General Meeting of Shareholders
BEIJING, July 2, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (CBPO) ("CBPO" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced the results of the Company's 2018 Annual General Meeting of Shareholders (the "Annual Meeting"), which was originally convened at 10:00 a.m. on Friday, June 29, 2018, and adjourned and re-convened at 10:00 a.m. on Monday, July 2, 2018. At the Annual Meeting, shareholders of the Company approved the re-election of each of Mr. Yungang Lu and Mr. Zhijun Tong as a Class III director to serve on the board of directors of the Company (the "Board") until the 2021 annual general meeting of shareholders, and ratified the appointment of KPMG Huazhen LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.
- Reuters•2 months ago
Ex-Warburg Pincus China head targets up to $1.5 bln for China fund - sources
Private-equity firm Centurium Capital, founded by former Warburg Pincus China head, is targeting to raise up to $1.5 billion in its China-focused fund to invest in healthcare and consumer sectors, two sources with knowledge of the matter said. The fundraising by Centurium - set up by David Li after he had worked with the U.S. buyout firm for 14 years - adds to a massive industry-wide pool of money for acquisitions in China, which is popular among investors given its rapid urbanization and rising incomes.
- ACCESSWIRE•2 months ago
Today’s Research Reports on Stocks to Watch: JD.com and China Biologic Products
NEW YORK, NY / ACCESSWIRE / June 19, 2018 / JD.com and China Biologic Products Holdings both saw gains in Monday trading. JD.com saw a modest rise after Wall Street learned that Google is investing $550 ...
- PR Newswire•2 months ago
China Biologic Announces Receipt of Non-Binding Acquisition Proposal
BEIJING, June 19, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (CBPO) ("CBPO" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its board of directors (the "Board") has received an unsolicited, preliminary non-binding proposal letter from CCRE Holdings Limited, a wholly owned subsidiary of CITIC Capital Holdings Limited (together with its affiliates, "CITIC"), pursuant to which CITIC proposes to acquire all of the outstanding shares of the Company not already owned by CITIC for US$110 in cash per share. A copy of the proposal letter is attached hereto as Annex A.
- PR Newswire•2 months ago
WeissLaw LLP Investigates China Biologic Products Holdings, Inc.
NEW YORK , June 18, 2018 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of China Biologic Products Holdings, Inc. ...
- Motley Fool•2 months ago
Here's Why China Biologic Products Holdings Inc. Soared as Much as 25.8% Today
The Chinese plasma manufacturer might be acquired for $110 per share.
- Investor's Business Daily•2 months ago
Stocks Slide; Intel Downgraded; JD.com Spikes On Google Deal
Stocks slid lower Monday as global markets remained rattled by the U.S.-China trade standoff. China stocks were highly active, however, led by JD.com.
- Reuters•2 months ago
CITIC Capital offers to buy China Biologic for $110 per share
A unit of Chinese investment firm CITIC Capital Holdings Ltd said on Monday it has offered to buy U.S.-listed biotech firm China Biologic Products Holdings Inc , in a deal valuing the company at $3.65 ...
- Reuters•2 months ago
Investment firm CITIC Capital offers to buy China Biologic Products
A unit of Chinese investment firm CITIC Capital Holdings Ltd has offered to buy U.S.-listed biotech firm China Biologic Products Holdings Inc. The unit, CCRE, offered $110 in cash for each share of China ...
- PR Newswire•2 months ago
China Biologic Receives CFDA Clinical Trial Approval for Human Fibrin Sealant
BEIJING, June 11, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that Shandong Taibang Biological Products Co. Ltd., the Company's majority-owned subsidiary, recently obtained approval from the China Food and Drug Administration (the "CFDA") to begin human clinical trials on its Human Fibrin Sealant ("Fibrin Sealant") product. Fibrin Sealant is intended to be used as an adjunct to hemostasis on patients undergoing surgery in case traditional surgical techniques such as sutures, ligatures, and cauteries are ineffective or impractical.
- GlobeNewswire•2 months ago
Analysis: Positioning to Benefit within China Biologic Products, Merus N.V, Adient, G1 Therapeutics, Westport Fuel, and AppFolio — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, June 06, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of China ...
- Simply Wall St.•3 months ago
Was China Biologic Products Holdings Inc’s (NASDAQ:CBPO) Earnings Decline Part Of A Broader Industry Downturn?
Assessing China Biologic Products Holdings Inc’s (NASDAQ:CBPO) performance as a company requires looking at more than just a years’ earnings data. Below, I will run you through a simple senseRead More...
- ACCESSWIRE•3 months ago
Blog Exposure - Portola Pharma Receives Approval from FDA for Its Lead Candidate
LONDON, UK / ACCESSWIRE / May 08, 2018 / If you want access to our free research report on Portola Pharma, Inc. (NASDAQ: PTLA), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=PTLA as the Company's latest news hit the wire. On May 03, 2018, the Company announced that the US Food and Drug Administration (FDA) has approved its lead candidate, Andexxa®, the first and only antidote indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. Active-Investors.com is currently working on the research report for China Biologic Products Holdings, Inc. (NASDAQ: CBPO), which also belongs to the Healthcare sector as the Company Portola Pharma.
- Associated Press•4 months ago
China Biologic Products: 1Q Earnings Snapshot
On a per-share basis, the Beijing-based company said it had net income of 92 cents. Earnings, adjusted for non-recurring costs, came to $1.21 per share. The biopharmaceutical company posted revenue of ...
- PR Newswire•4 months ago
China Biologic Reports Financial Results for the First Quarter of 2018
--1Q18 Total Sales Up 13.7% YoY and Non-GAAP Adjusted Net Income Up 2.1% YoY in RMB terms, or Total Sales Up 23.0% YoY to $112.5 Million and Net Income Up 5.3% YoY to $31.6 Million in USD terms-- BEIJING ...
- Simply Wall St.•4 months ago
Is There An Opportunity With China Biologic Products Holdings Inc’s (NASDAQ:CBPO) 39% Undervaluation?
Does the share price for China Biologic Products Holdings Inc (NASDAQ:CBPO) reflect it’s really worth? Today, I will calculate the stock’s intrinsic value using the discounted cash flow (DCF) method.Read More...
- Simply Wall St.•4 months ago
Has China Biologic Products Holdings Inc (NASDAQ:CBPO) Got Enough Cash?
Stocks with market capitalization between $2B and $10B, such as China Biologic Products Holdings Inc (NASDAQ:CBPO) with a size of US$2.81B, do not attract as much attention from the investingRead More...
Markit•5 months agoSee what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.
China Biologic Products Holdings Inc NASDAQ/NGS:CBPO
